Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Observational Study About the Use of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02245555

Enrollment

1060

Registered

2014-09-19

Start date

2006-04-30

Completion date

Unknown

Last updated

2014-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Hyperplasia

Brief summary

Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia

Interventions

DRUGTamsulosin

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients older than 21 years old diagnosed with benign prostatic hyperplasia (BPH), who require pharmacological treatment to relieve symptoms and improve their quality of life, according to physician's judgment. The study will include naïve patients and patients not responding to previous therapy who receive Secotex as alternative or complementary treatment. The decision to treat a patient with Tamsulosin must be based on the best standard accepted in the clinical practice and must be carried out following Secotex (Tamsulosin) prescription information

Exclusion criteria

* Patients with known hypersensitivity to Tamsulosin or any of its ingredients, history of orthostatic hypotension or severe liver failure, or with any missing data required to complete the questionnaire are excluded

Design outcomes

Primary

Measure	Time frame
Number of patients with adverse events	up to 21 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026